The Status of p53 Oligomeric and Aggregation States in Cancer
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Despite being referred to as the guardian of the genome, when impacted by mutations, p53 can lose its protective functions and become a renegade. The malignant transformation of p53 occurs on multiple levels, such as altered DNA binding properties, acquisition of novel cellular partners, or associating into different oligomeric states. The consequences of these transformations can be catastrophic. Ongoing studies have implicated different oligomeric p53 species as having a central role in cancer biology; however, the correlation between p53 oligomerization status and oncogenic activities in cancer progression remains an open conundrum. In this review, we summarize the roles of different p53 oligomeric states in cancer and discuss potential research directions for overcoming aberrant p53 function associated with them. We address how misfolding and prion-like amyloid aggregation of p53 seem to play a crucial role in cancer development. The misfolded and aggregated states of mutant p53 are prospective targets for the development of novel therapeutic strategies against tumoral diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mutations in TP53 not only change its conformation but also cause p53 aggregation”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [146]
In the citing paper
“p53 aggregation in cells is more consequential than conformational changes.146,147”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · cited 2×
“favors p53 transcriptional activity [13,14].”
BackgroundMuller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1×
“In resting cells, p53 transcriptional activity is tightly controlled by the E3 ubiquitin protein ligase, MDM2, leading to p53 degradation and rapid turnover [8].”
BackgroundCytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106 · cited 2×
“Cytosolic p53 is involved in induction of mitochondrial outer membrane permeabilization (MOMP) [49] which ultimately results in the release of pro-apoptotic effectors and inhibition of autophagy (Reference [46] and citations therein) (Figure 3B).”
BackgroundStommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., & Wahl, G. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1660 · Cited by 738 · cited 1×
“Because the p53 tetramerization domain displays a leucine-rich nuclear export signal (NES) that is occluded in active tetramers, but not in dimers, cytosolic p53 is presumably dimeric [47].”
BackgroundGain of function of mutant p53 by coaggregation with multiple tumor suppressors
Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543
Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth
Zhu, J., Sammons, M. A., Donahue, G., Dou, Z., Vedadi, M., Getlik, M., Barsyte-Lovejoy, D., Al-awar, R., Katona, B. W., Shilatifard, A., et al. (2015) · Nature · doi:10.1038/nature15251 · Cited by 493
Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 434
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341 · cited 2×
“A major challenge in obtaining such detail is structural polymorphism, as even short peptides corresponding to the p53 DBD aggregation sequence present varied topologies and fibril profiles [83,85] (Figure 4).”
Background
Research works printed but not linked: 70
- Lane, 1979, T antigen is bound to a host protein in SV40-transformed cells, Nature, 278, 261, 10.1038/278261a0 · DOI · Paper page
- Linzer, 1979, Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells, Cell, 17, 43, 10.1016/0092-8674(79)90293-9 · DOI · Paper page
- Rangel, 2015, Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer, Front. Oncol., 5, 97
- Costa, 2016, Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?, Cold Spring Harb. Perspect. Biol., 8, a023614, 10.1101/cshperspect.a023614 · DOI · Paper page
- Kastan, 1992, A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia, Cell, 71, 587, 10.1016/0092-8674(92)90593-2 · DOI · Paper page
- Lowe, 1993, p53 is required for radiation-induced apoptosis in mouse thymocytes, Nature, 362, 847, 10.1038/362847a0 · DOI · Paper page
- Halazonetis, 1993, Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants, EMBO J., 12, 5057, 10.1002/j.1460-2075.1993.tb06199.x · DOI · Paper page
- Joerger, 2016, The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches, Annu. Rev. Biochem., 85, 375, 10.1146/annurev-biochem-060815-014710 · DOI · Paper page
- Saito, 2003, Phosphorylation site interdependence of human p53 post-translational modifications in response to stress, J. Biol. Chem., 278, 37536, 10.1074/jbc.M305135200 · DOI · Paper page
- Appella, 2001, Post-translational modifications and activation of p53 by genotoxic stresses, Eur. J. Biochem., 268, 2764, 10.1046/j.1432-1327.2001.02225.x · DOI · Paper page
- Sakamuro, 1997, The polyproline region of p53 is required to activate apoptosis but not growth arrest, Oncogene, 15, 887, 10.1038/sj.onc.1201263 · DOI · Paper page
- Gu, 1997, Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain, Cell, 90, 595, 10.1016/S0092-8674(00)80521-8 · DOI · Paper page
- Espinosa, 2001, Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment, Mol. Cell, 8, 57, 10.1016/S1097-2765(01)00283-0 · DOI · Paper page
- Leroy, 2014, TP53 mutations in human cancer: Database reassessment and prospects for the next decade, Hum. Mutat., 35, 672, 10.1002/humu.22552 · DOI · Paper page
- Taylor, 1996, p53 mutations in bladder tumors from arylamine-exposed workers, Cancer Res., 56, 294
- Sun, 1996, A novel p53 germline alteration identified in a late onset breast cancer kindred, Oncogene, 13, 407
- Silva, 2018, Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer, Acc. Chem. Res., 51, 181, 10.1021/acs.accounts.7b00473 · DOI · Paper page
- Milner, 1991, Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation, Cell, 65, 765, 10.1016/0092-8674(91)90384-B · DOI · Paper page
- Vaughan, 2012, p53 mutants induce transcription of NF-kappaB2 in H1299 cells through CBP and STAT binding on the NF-kappaB2 promoter and gain of function activity, Arch. Biochem. Biophys., 518, 79, 10.1016/j.abb.2011.12.006 · DOI · Paper page
- Will, 1998, Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing, Proc. Natl. Acad. Sci. USA, 95, 13681, 10.1073/pnas.95.23.13681 · DOI · Paper page
- Fontemaggi, 2011, ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters, OMICS, 15, 305, 10.1089/omi.2010.0084 · DOI · Paper page
- Liu, 2011, TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73, Mol. Cell Biol., 31, 4464, 10.1128/MCB.05574-11 · DOI · Paper page
- Girardini, 2011, A Pin1/mutant p53 axis promotes aggressiveness in breast cancer, Cancer Cell, 20, 79, 10.1016/j.ccr.2011.06.004 · DOI · Paper page
- Martynova, 2012, Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63, Oncotarget, 3, 132, 10.18632/oncotarget.447 · DOI · Paper page
- Song, 2007, p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM, Nat. Cell Biol., 9, 573, 10.1038/ncb1571 · DOI · Paper page
- Restle, 2008, Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants, Nucleic Acids Res., 36, 5362, 10.1093/nar/gkn503 · DOI · Paper page
- Rajagopalan, 2011, Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53, Nucleic Acids Res., 39, 2294, 10.1093/nar/gkq800 · DOI · Paper page
- Jeffrey, 1995, Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms, Science, 267, 1498, 10.1126/science.7878469 · DOI · Paper page
- Stenger, 1992, Formation of stable p53 homotetramers and multiples of tetramers, Mol. Carcinog., 5, 102, 10.1002/mc.2940050204 · DOI · Paper page
- Wang, 1995, Interaction of p53 with its consensus DNA-binding site, Mol. Cell Biol., 15, 2157, 10.1128/MCB.15.4.2157 · DOI · Paper page
- Stenger, 1994, p53 oligomerization and DNA looping are linked with transcriptional activation, EMBO J., 13, 6011, 10.1002/j.1460-2075.1994.tb06947.x · DOI · Paper page
- Okorokov, 2006, The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity, EMBO J., 25, 5191, 10.1038/sj.emboj.7601382 · DOI · Paper page
- Kearns, 2016, Two p53 tetramers bind one consensus DNA response element, Nucleic Acids Res., 44, 6185, 10.1093/nar/gkw215 · DOI
- Vyas, 2017, Diverse p53/DNA binding modes expand the repertoire of p53 response elements, Proc. Natl. Acad. Sci. USA, 114, 10624, 10.1073/pnas.1618005114 · DOI · Paper page
- Pedrote, 2020, Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers, iScience, 23, 100820, 10.1016/j.isci.2020.100820 · DOI · Paper page
- Gaglia, 2013, Activation and control of p53 tetramerization in individual living cells, Proc. Natl. Acad. Sci. USA, 110, 15497, 10.1073/pnas.1311126110 · DOI · Paper page
- Katz, 2018, Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers, Genes Dev., 32, 430, 10.1101/gad.304071.117 · DOI
- Rangel, 2012, Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: Implications for cancer, J. Biol. Chem., 287, 28152, 10.1074/jbc.M112.340638 · DOI · Paper page
- Ghosh, 2017, p53 amyloid formation leading to its loss of function: Implications in cancer pathogenesis, Cell Death Differ., 24, 1784, 10.1038/cdd.2017.105 · DOI
- Clos, 2013, Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity, Biochem. Biophys. Res. Commun., 430, 963, 10.1016/j.bbrc.2012.11.130 · DOI
- Soteras, 2015, p53 protein aggregation promotes platinum resistance in ovarian cancer, Oncogene, 34, 3605, 10.1038/onc.2014.296 · DOI
- Pedrote, 2019, Loss of the p53 transactivation domain results in high amyloid aggregation of the Delta40p53 isoform in endometrial carcinoma cells, J. Biol. Chem., 294, 9430, 10.1074/jbc.RA119.007566 · DOI · Paper page
- Ishimaru, 2003, Fibrillar aggregates of the tumor suppressor p53 core domain, Biochemistry, 42, 9022, 10.1021/bi034218k · DOI · Paper page
- Ishimaru, 2003, Conversion of Wild-type p53 Core Domain into a Conformation that Mimics a Hot-spot Mutant, J. Mol. Biol., 333, 443, 10.1016/j.jmb.2003.08.026 · DOI
- Levy, 2011, Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors, Int. J. Biochem. Cell Biol., 43, 60, 10.1016/j.biocel.2010.10.017 · DOI · Paper page
- Wang, 2013, Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase, Neurol. Sci., 34, 1421, 10.1007/s10072-012-1257-9 · DOI
- Klibanov, 2001, Accumulation of soluble and nucleolar-associated p53 proteins following cellular stress, J. Cell Sci., 114, 1867, 10.1242/jcs.114.10.1867 · DOI · Paper page
- Latonen, 2019, Phase-to-Phase with Nucleoli—Stress Responses, Protein Aggregation and Novel Roles of RNA, Front. Cell Neurosci., 13, 151, 10.3389/fncel.2019.00151 · DOI · Paper page
- Audas, 2016, Adaptation to Stressors by Systemic Protein Amyloidogenesis, Dev. Cell, 39, 155, 10.1016/j.devcel.2016.09.002 · DOI · Paper page
- Silva, 2016, The “Jekyll and Hyde” Actions of Nucleic Acids on the Prion-like Aggregation of Proteins, J. Biol. Chem., 291, 15482, 10.1074/jbc.R116.733428 · DOI · Paper page
- Kamagata, 2020, Liquid-like droplet formation by tumor suppressor p53 induced by multivalent electrostatic interactions between two disordered domains, Sci. Rep., 10, 580, 10.1038/s41598-020-57521-w · DOI · Paper page
- Cordeiro, 2019, Modulation of p53 and prion protein aggregation by RNA, Biochim. Biophys. Acta Proteins Proteom., 1867, 933, 10.1016/j.bbapap.2019.02.006 · DOI
- Yang, D.S.S.A., Davtyan, A., Fathi, M., Safari, M.S., Klindziuk, A., Barton, M.C., Varadarajan, N., Kolomeisky, A.B., and Vekilov, P.G. (2020). Mesoscopic Liquid Clusters Represent a Distinct Condensate of Mutant p53. bioRxiv. · DOI
- Yoshida, 2004, Binding of RNA to p53 regulates its oligomerization and DNA-binding activity, Oncogene, 23, 4371, 10.1038/sj.onc.1207583 · DOI
- Kovachev, 2017, Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain, J. Biol. Chem., 292, 9345, 10.1074/jbc.M116.762096 · DOI · Paper page
- Safari, 2019, Anomalous Dense Liquid Condensates Host the Nucleation of Tumor Suppressor p53 Fibrils, iScience, 12, 342, 10.1016/j.isci.2019.01.027 · DOI · Paper page
- Suwiwat, 2004, Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer, Clin. Cancer Res., 10, 2491, 10.1158/1078-0432.CCR-03-0146 · DOI · Paper page
- Gerotziafas, 2008, Clinical studies with anticoagulants to improve survival in cancer patients, Pathophysiol. Haemost. Thromb., 36, 204, 10.1159/000175158 · DOI
- Falanga, 2007, Heparin in tumor progression and metastatic dissemination, Semin. Thromb. Hemost., 33, 688, 10.1055/s-2007-991536 · doi:10.1055/s-2007-991536
- Alur, 2016, Anti-tumor effects of bemiparin in HepG2 and MIA PaCa-2 cells, Gene, 585, 241, 10.1016/j.gene.2016.03.044 · DOI
- Hsu, H.K., Hsu, K.H., Cheng, Y.M., Suen, H.Y., and Peng, S.F. (2018). Development and In Vitro Evaluation of Linear PEI-Shelled Heparin/Berberine Nanoparticles in Human Osteosarcoma U-2 OS Cells. Molecules, 23. · DOI
- Karbownik, 2013, Hyaluronan: Towards novel anti-cancer therapeutics, Pharmacol. Rep., 65, 1056, 10.1016/S1734-1140(13)71465-8 · DOI
- Zhao, 2019, Bioengineered tumor microenvironments with naked mole rats high-molecular-weight hyaluronan induces apoptosis in breast cancer cells, Oncogene, 38, 4297, 10.1038/s41388-019-0719-4 · DOI
- Pedrote, 2018, Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer, J. Biol. Chem., 293, 11374, 10.1074/jbc.RA118.003285 · DOI · Paper page
- Baud, 2018, Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines, Eur. J. Med. Chem., 152, 101, 10.1016/j.ejmech.2018.04.035 · DOI · Paper page
- Rangel, 2019, p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells, J. Biol. Chem., 294, 3670, 10.1074/jbc.RA118.004671 · DOI · Paper page
- Campos, 2018, Resveratrol prevents p53 aggregation in vitro and in breast cancer cells, Oncotarget, 9, 29112, 10.18632/oncotarget.25631 · DOI · Paper page
- Cino, 2016, Aggregation tendencies in the p53 family are modulated by backbone hydrogen bonds, Sci. Rep., 6, 32535, 10.1038/srep32535 · DOI · Paper page
- Chen, 2017, Polyarginine and its analogues inhibit p53 mutant aggregation and cancer cell proliferation in vitro, Biochem. Biophys. Res. Commun., 489, 130, 10.1016/j.bbrc.2017.05.111 · DOI
- Lima, 2020, Biophysical characterization of p53 core domain aggregates, Biochem. J., 477, 111, 10.1042/BCJ20190778 · DOI
Cited by
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- de Oliveira, G. A. P., Petronilho, E. C., Pedrote, M. M., Marques, M. A., Vieira, T. C. R. G., Cino, E. A., & Silva, J. L.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2020-04-04
- Volume
- 10
- Issue
- 4
- Pages
- 548
- ISSN
- 2218-273X
- Cited by
- 56
- References
- 15
- Language
- en
- Funders
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (210008/2018)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (465395/2014-7)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.